Rasmussen, Søren

Insulin degludec is not associated with a delayed or diminished response to hypoglycaemia compared with insulin glargine in type 1 diabetes: a double-blind randomised crossover study

Koehler, G., Heller, S., Korsatko, S., Roepstorff, C., Rasmussen, S., Haahr, H., & Pieber, T. R. (2014) · Diabetologia

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 29

Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6

Husain, M., Consoli, A., De Remigis, A., Pettersson Meyer, A. S., Rasmussen, S., & Bain, S. (2022) · Cardiovascular Diabetology

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 16

SEMAGLUTIDE REDUCES HIGH-SENSITIVITY CRP LEVELS ACROSS DIFFERENT TREATMENT FORMULATIONS: EXPLORATORY ANALYSES OF SUSTAIN 3 AND PIONEER 1, 2 AND 5 TRIALS

Rosenstock, J., Capehorn, M., De Remigis, A., Rasmussen, S., Weimers, P., & Mosenzon, O. (2021) · Journal of the American College of Cardiology

Diabetes Treatment and ManagementLipoproteins and Cardiovascular Health

Cited by 6

Effects of once‐weekly subcutaneous semaglutide on coronary artery disease outcomes in patients with type 2 diabetes with or at high risk for cardiovascular disease: Insights from the SUSTAIN‐6 trial

Kolkailah, A. A., Lingvay, I., Dobrecky‐Mery, I., Aharonovich, A., David, J., Holse, C., Rasmussen, S., & McGuire, D. K. (2023) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 6